Elicio reaches alignment with FDA on ELI-002 registrational strategy

Elicio Therapeutics (ELTX) announced that it has received supportive feedback in an End of Phase 1 Type B meeting with the U.S. Food and Drug Administration, FDA, regarding the registrational strategy for ELI-002. Based on the feedback received, Elicio would expect to file a Biologics License Application, BLA, if supported by a planned Phase 3 trial.